Resources
16 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 3/21/2022 (updated 3/27/2024)
People who inject drugs (PWID) are likely to experience wounds and infection related to their injection drug use. Common wounds and infections experienced by PWID include blood poisoning (septicemia), infection of the heart lining (endocarditis), tetanus, hepatitis, bruising, collapsed veins, abscesses and blood clots. Preventing and caring for wounds in PWID requires special consideration of the conditions surrounding drug use.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 11/27/2019 (updated 3/28/2024)
This guide is aimed at people who inject drugs to help reduce some of the problems caused by injecting.
Posted 9/18/2020 (updated 3/29/2024)
The National Alliance of State and Territorial AIDS Directors (NASTAD) hosted the Hepatitis A and Hepatitis B Vaccination Efforts in People Who Inject Drugs webinar last week, September 10, 2020. The session featured Centers for Disease Control and Prevention subject matter experts who discussed the epidemiology of hepatitis A and hepatitis B in people who use and inject drugs and the rationale for the vaccination recommendations. The session also featured several jurisdictions and partner organizations who shared their lessons learned and best practices for reaching and implementing vaccination services in this community.
Posted 10/5/2020 (updated 3/29/2024)
This review looks at evidence and program models for alternatives to hospitalization to treat serious infections in people who inject drugs.
Posted 10/12/2020 (updated 3/29/2024)
This article discusses findings from a study published in the Journal of Viral Hepatitis which addresses the question of HCV testing frequency in people who inject drugs.
Posted 7/21/2021 (updated 4/2/2024)
Goals: Increase knowledge of harm reduction principles, strategies, and resources, increase knowledge of managed use, abstinence, and safer use to meet people who use drugs where they are at, provide a safe environment (plenaries and breakouts) to discuss licit and illicit drug use as a multi-faceted phenomenon requiring successful interventions and policies and increase knowledge of stigma as it relates to harm reduction principles and practices.
Expanding The Circle of Care: A Practical Guide to Syringe Services for Tribal and Rural Communities
Posted 8/3/2021 (updated 4/2/2024)
This guide presents practical information on establishing and maintaining syringe services in rural and tribal communities based on experiences of the Bad River Band of Lake Superior Chippewa.
Posted 9/15/2021 (updated 4/3/2024)
The UNODC Regional Program Office for Eastern Europe (Kiev, Ukraine), in collaboration with the Humanitarian Action Fund (St. Petersburg, Russia), issues recommendations on web outreach for people who use drugs (PWUD), including people who use new psychoactive substances (NPS). Web outreach is a method of establishing contact, counseling, involving and retaining PWUD in harm reduction programs through websites, social networks, instant messengers, specialized forums, including Darknet platforms.